Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Feasibility of UMC119-06 in COPD
NCT04206007Phase 1Unknown
- Sponsor
- Meridigen Biotech Co., Ltd.
- Start
- Jun 2020
- Primary completion
- Dec 2023
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of umc119-06 in chronic obstructive pulmonary disease (COPD), sponsored by Meridigen Biotech Co., Ltd. Primary endpoint: Incidence and frequency of adverse events at 3 months. Status: unknown.
02
Drugs
umc119-06
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04206007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04206007.